NOVAVAX INC
8-K, 2001-01-19
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: AMERIPRIME FUNDS, 497, 2001-01-19
Next: NOVAVAX INC, 8-K, EX-10.1, 2001-01-19


<PAGE>   1


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                    CURRENT REPORT UNDER SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): January 8, 2001


                                  NOVAVAX, INC.
                                  -------------
             (Exact name of registrant as specified in its charter)


<TABLE>
<CAPTION>
              DELAWARE                0-26770                22-2816046
              --------                -------                ----------
<S>                                 <C>                   <C>
  (State or other jurisdiction      (Commission           (I.R.S. Employer
of incorporation or organization)     File No.)           Identification No.)
</TABLE>


               8320 GUILFORD ROAD, COLUMBIA, MD            21046
               --------------------------------            -----
           (Address of principal executive offices)      (Zip code)


                                 (301) 854-3900
                                 --------------
               Registrant's telephone number, including area code


                                 NOT APPLICABLE
                                 --------------
          (Former name or former address, if changed since last report)


<PAGE>   2


                                  NOVAVAX, INC.
                       ITEMS TO BE INCLUDED IN THIS REPORT



ITEM 2.    ACQUISITION OR DISPOSITION OF ASSETS.

                Effective as of January 8, 2001, Novavax, Inc. ("Novavax")
        acquired the rights to AVC(TM) (sulfanilamide) vaginal anti-infective
        cream and suppositories, in the U.S. and Puerto Rico from King
        Pharmaceuticals, Inc. ("King") for $3.3 million.



ITEM 5.    OTHER EVENTS.

                Effective January 8, 2001, Novavax entered into a Copromotion
        Agreement with King, for Estrasorb(TM), Novavax's topical, transdermal
        estrogen replacement therapy, in the United States and Puerto Rico.
        Novavax granted to King an exclusive license to promote, market,
        distribute and sell Estrasorb(TM), worldwide, except in the United
        States, Canada, Italy, Netherlands, Greece, Switzerland and Spain.

                Also, effective January 8, 2001, as part of the Copromotion
        Agreement, King and Novavax will jointly market King's product,
        Nordette(R) (an oral contraceptive) in the United States and Puerto
        Rico.

                A copy of the press release relating to the events in Item 2.
        and Item 5. above, was issued on January 8, 2001 and is attached as
        Exhibit 99.1 and incorporated herein by this reference.


ITEM 7.    FINANCIAL STATEMENTS, PRO-FORMA FINANCIAL INFORMATION AND EXHIBITS.

           (a)  Financial Statements of Businesses Acquired. It is impractical
                at this time to provide this information. This information will
                be filed as soon as practical, but in no event not later than
                March 23, 2001.

           (b)  Pro Forma Financial Information. It is impractical at this
                time to provide this information. This information will be filed
                as soon as practical, but in no event not later than March 23,
                2001.

           (c)  Exhibits.

<PAGE>   3



<TABLE>
<S>       <C>
          10.1  Agreement for Purchase and Sale of Assets Relating to AVC(TM)
                Product Line dated as of January 8, 2001, by and between
                Novavax, Inc. and King Pharmaceuticals, Inc.

          10.2  Copromotion Agreement dated as of January 8, 2001, between
                Novavax, Inc. and King Pharmaceuticals, Inc.

          10.3  Exclusive License and Distribution Agreement dated as of
                January 8, 2001, between Novavax, Inc. and King Pharmaceuticals,
                Inc.

          99.1  Press Release of Novavax, Inc. dated January 8, 2001.
</TABLE>


<PAGE>   4


                                    SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934,
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   NOVAVAX, INC.



Date: January 19, 2001                 By: /s/ Dennis W. Genge
                                          --------------------------------
                                           Dennis W. Genge, Vice President
                                           And Chief Financial Officer/Treasurer

Top Judgements:
101034761 Saskatchewan Ltd. v Mossing | Aug 24, 2022
Waste Control Services Inc. v International Union of Operating Engineers, Local No. 115 | Aug 12, 2022
RJM56 Holdings Inc. c. Bazinet | Aug 17, 2022
Sherwood v The Owners, Strata Plan VIS 1549 | Aug 9, 2022
WCAT Decision A2001487 | Aug 8, 2022
City of Hamilton v Ontario Water Employees’ Association | Sep 12, 2022
Century Services Corp. v. LeRoy | Jul 8, 2022
United Food and Commercial Workers, Local 175 v Metro Ontario Inc. | Jul 4, 2022
Langmaid’s Island Corporation v Lake of Bays | Sep 12, 2022
WCAT Decision A2102416 | Jul 22, 2022
Inquiry about McAbee Fossil beds | Jul 14, 2022
1088558 Ontario Inc. v. Musial | Sep 16, 2022
Biogen Canada Inc. v. Pharmascience Inc. | Aug 8, 2022
CIC Management Services Inc. v City of Toronto | Jul 21, 2022
Bonterra Energy Corp v Rosells’ Enterprises Ltd | Aug 31, 2022
WCAT Decision A2100606 | Aug 17, 2022
Leffler v Aaron Behiel Legal Professional Corporation | Jun 30, 2022
Espartel Investments v. MTCC No. 993 | Aug 19, 2022
Onespace Unlimited Inc. v. Plus Development Group Corp. | Sep 19, 2022
Professional Institute of the Public Service of Canada v. Canada Revenue Agency | Jun 23, 2022
Community Savings Credit Union v. Bodnar | Jul 29, 2022
Galperti SRL v F.I.A.L. Finanziaria Industrie Alto Lario S.P.A | Jun 30, 2022
WCAT Decision A2102352 | Jul 6, 2022
WCAT Decision A2102306 | Jul 25, 2022
Thrive Capital Management Ltd. v. Noble 1324 Queen Inc. | Jul 12, 2022
Questor Technology Inc v Stagg | Sep 8, 2022
MediPharm v. Hexo and Hwang | Jul 25, 2022
Immunization rates & vaccine hesitancy | Aug 17, 2022
Morabito v. British Columbia Securities Commission | Aug 12, 2022
Killeleagh v Mountain View County (Development Authority) | Aug 24, 2022
Quality Control Council v Stanley Inspection Canada Ltd. | Sep 9, 2022
British Columbia Investment Management Corporation | Aug 17, 2022
Abbeylawn Manor Living Inc. v Sevice Employees International Union, Local 1 Canada | Jul 5, 2022
Windrift Adventures Inc. et al. v. Chief Animal Welfare Inspector | Aug 18, 2022
Irani and Khan v. Registrar, Motor Vehicle Dealers Act | Jul 14, 2022
CP REIT Ontario Properties Limited v City of Toronto | Aug 12, 2022
Potash Corporation of Saskatchewan Inc. v. The Queen | Jul 7, 2022
Wong v. Pretium Resources Inc. | Jul 22, 2022
Labourers' International Union of North America, Local 183, Union v Mulmer Services Ltd. | Aug 5, 2022
City of Mississauga v. Hung | Sep 22, 2022
Secretary of the Ministry of Health v The New South Wales Nurses and Midwives' Association (28 September 2022)
Orewa Community Church v Minister for Covid-19 Response (16 August 2022)
Yeshiva College Bondi Limited v NSW Education Standards Authority (15 August 2022)
Moreland Planning Scheme Amendment C208more | Heritage Nominations Study | Panel Report | 15 July 2022
New Zealand Tegel Growers Association Incorporated | 2 August 2022
Farrow-Smith and Comcare (Compensation) | 26 September 2022
Evolution Fleet Services Pty Ltd v Allroads Plant Pty Ltd | 14 September 2022
656621 B.C. Ltd. v David Moerman Painting Ltd. | Sep 27, 2022
Fraser Valley Packers Inc. v Raiwal Holdings Ltd | Sep 26, 2022
Parmar v Tribe Management Inc. | Sep 26, 2022
DES Studio inc. c. Shuchat | Sep 26, 2022
Van-Kam Freightways Ltd. v Teamsters Local Union No. 31 | Sep 28, 2022
Rogers Communication Inc. v British Columbia | Sep 28, 2022
Alderbridge Way GP Ltd. | Sep 28, 2022
VIMY RESOURCES LTD | 11 August 2022
METALICITY LTD -v- NEX METALS EXPLORATIONS LTD | 22 July 2022
Thorndon Quay Collective Inc v Wellington City Council | 14 September 2022
Rongotai Investments Ltd v Land Valuation Tribunal | 19 July 2022
Peet Limited Pty Ltd v Greater Dandenong City Council | 23 August 2022
The WSD v. City of Winnipeg et al. | Oct 3, 2022
40 Days for Life v. Dietrich et. al. | Sep 30, 2022
University of Saskatchewan Faculty Association v University of Saskatchewan | Sep 29, 2022
R.A.B. Properties Ltd. v Canadian Horizons (182A) Development Corp. | Oct 3, 2022
Nissan Canada Inc. v. Mueller | Oct 5, 2022
Henni v Food Network Canada Inc. | Oct 3, 2022

© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission